Eight-Year Data Confirm Long-Term Durability of Edwards Lifesciences' RESILIA Tissue

Published: 2025-04-21 11:50:25 ET EW

CAIRO - Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.

For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two decades ago. Today, RESILIA tissue is used in a wide range of Edwards' surgical and transcatheter platforms, including the INSPIRIS RESILIA aortic surgical valve, the KONECT RESILIA aortic surgical valve conduit, the MITRIS RESILIA mitral surgical valve and the SAPIEN 3 Ultra RESILIA transcatheter aortic heart valve. Edwards' INSPIRIS RESILIA and SAPIEN 3 Ultra RESILIA valves are supported by extensive, long-term clinical evidence which is the result of three decades of innovation and expertise, leveraging the proven Carpentier-Edwards PERIMOUNT platform.

'These highly anticipated data provide strong clinical evidence of the excellent durability of RESILIA tissue in surgical valves,' said Tsuyoshi Kaneko, M.D., John M. Shoenberg Chair of Cardiovascular Disease, Chief of Cardiac Surgery at Washington University in St. Louis and lead author of the study. 'This level of performance is critical to reducing reinterventions and enabling more effective lifetime management for patients.'

Presented at the Heart Valve Society Annual Meeting, the study of 947 patients marks the first long-term, propensity-matched comparison between RESILIA tissue and non-RESILIA tissue surgical aortic valves. The RESILIA tissue data from the trial reported encouraging results through eight years, with low rates of structural valve deterioration (99.3% freedom from SVD in the RESILIA tissue group versus 90.5% in the non-RESILIA tissue group, p